An immunosuppressed rat model was used to investigate the anti-Cryptosporidium parvum activity of sinefungin. In infected animals, oral sinefungin therapy resulted in a dose-related suppression of oocyst shedding, which correlated with oocyst disappearance from ileal sections. When administered prior to or on the day of oocyst challenge, sinefungin successfully prevented infection. These data suggest that sinefungin could be considered as a candidate molecule in the treatment of human cryptosporidiosis, considered to be the most significant enteric opportunistic infection in AIDS.
Cryptospondium parvum is a coccidial protozoan that primarily inhabits the brush border of enterocytes and causes diarrheal disease in various mammalian host species (8) . In immunocompetent humans, C. parvum infection may produce a self-resolving diarrhea (6, 7, 23) . In immunocompromised patients, it causes severe and prolonged diarrhea, and it is considered one of the most important enteric opportunistic infections in AIDS patients. So far, on the basis of therapeutic outcomes, limited or no effect of proposed anti-C parvum therapies has been observed (8) .
In vitro models provide oocysts for only a short period of time and drug screening is not easily performed (13) . Thus, immunocompromised adult animal models with chronic, life-threatening infections which mimic the status of patients are needed to properly evaluate candidate therapies. We have developed an animal model with immunosuppressed adult rats, and several drugs have been tested as both curative and preventive agents (5) . The present report shows that sinefungin exhibits a unique curative and preventive activity against C. parvum infection in this model.
The anticryptosporidial activity of sinefungin in immunosuppressed Sprague-Dawley rats was evaluated. As described earlier, animals used in these experiments weighed 200 to 250 g and their feces were free of C parvum oocysts before the study (4 In addition, the number of rats shedding oocysts at the end of the experiment in each group is given as the ratio of the number of shedder rats to the total number of animals studied in the group. Histologic examination was performed on three rats in each experimental group. The distal segment of ileus was cut, fixed, and embedded in paraffin, and 4-,um sections were either stained with hematoxylin-eosin or revealed by using an immunofluorescent anticryptosporidial antibody (18) . To correct for the patchy ileal localization of the parasite, 10 In group 2, rats were immunosuppressed, challenged with C. parvum oocysts (day 0), and treated with sinefungin easily solubilized in water (10 ml per rat per 24 h). In all experiments, it was verified that the drug had taken effect within 6 h.
In group 3, rats were immunosuppressed but not challenged, and no drugs were administered. Controls were established so that no spontaneous infection occurred in this group of rats during the time of the experiments.
Because immunosuppressed rats are susceptible to opportunistic infections such as Pneumocystis carinii pneumonia or aspergillosis, only rats surviving 7 days or more after challenge were included in the study. On day 7, the overall mortality rate of immunosuppressed animals was not significantly different between sinefungin-treated (mean, 16% of the animals) and nontreated (mean, 12% of the animals) (P > 0.5). In C. parvum-challenged animals, chronic oocyst shedding was ascertained from day 7 (in separate experiments, all immunocompetent rats did not shed oocysts over 4 to 7 days after challenge).
In the first series of experiments, the anticryptosporidial curative activity of sinefungin was demonstrated. Sinefungin was given from days 7 to 21, and oocyst excretion was measured from day 14 to day 21. As shown in Table 1 , there was a dramatic decrease in oocyst excretion under sinefungin therapy.
The activity of sinefungin was found to be dose related in the range of 0.01 to 10.0 mg/kg of body weight per 24 h ( Table 2) .
The preventive activity of sinefungin was ascertained in two series of experiments. As shown in Tables 3 and 4 , preventive therapy with sinefungin was effective, and efficiency was dependent on the duration of treatment prior to C. parvum challenge.
Three to 10 days after cessation of curative therapy with 5 to 10 mg/kg/day, a reappearance of oocyst shedding was observed in 4 of 11 of animals which did not shed oocysts on day 21. With the preventive protocol, with sinefungin at a dose regimen of from 0.01 to 0.5 mg/kg/day, shedding observed on the seventh day after discontinuation of therapy ranged from 285 to 5% of the mean excretion in control untreated animals. At preventive-dose regimens of from 0.5 to 2 mg/kg/day, no oocyst shedding was observed up to 20 days after the end of therapy.
In ) a Mean excretion in the control untreated group, 4.49 + 6.51 (n = 10). In treated groups, means are statistically different from the mean in the control untreated group (P < 0.01), except for the group treated with 0.25 mg/kg of body weight per day (P = 0.1).
b Inhibition = 1 -(mean in the treated group)/(mean in the control untreated group) x 100. c Number of shedder rats in the control untreated group, 10 (100%). d Mean and standard deviation lower than 0.01. was found between both counting methods (r = 0.86 and r = 0.83 in sinefungin-treated and nontreated groups, respectivelY).
Present data confirm the validity of the hydrocortisonetreated, protein-deprived rat model as a tool to identify drugs with in vivo anticryptosporidial activity (4, 5) . Animals mimic features of cryptosporidiosis reported in AIDS patients, including biliary localizations which may constitute a remote parasite reservoir (3a) . However, similarly to dexamethasone-treated rats and unlike T-lymphocyte-depleted or -deficient mice, which may represent a closer AIDS cryptosporidiosis model, they do not develop diarrhea but exhibit a decreased volume of feces (4, 24, 28) .
Sinefungin is a natural nucleoside antibiotic produced by Streptomyces griseolus and S. incamatus (15, 16) . It was found to be effective as an antiprotozoal drug against Plasmodium falciparum (21, 27) , Leishmania spp. (1), American and African Trypanosoma spp. (9, 22) , Toxoplasma gondii, and Entamoeba histolytica (10) . The biochemical mechanism of the antiparasitic activity of sinefungin possibly involves transmethylation reactions or enzymes of polyamine biosynthesis (10) . It was shown that sinefungin has an inhibitor activity in vitro against the transmethylase of T. gondii (11) . Both natural and synthetic sinefungins exhibit an antileishmanial activity, and the results of several analogous studies with derivative drugs have provided additional information on the minimal active structure for antiprotozoal activity (2, 3, 26) . Compared with other drugs, the activity of sinefungin seems very significant. Indeed, the list of inconclusive attempts to treat C. parvum in immunocompromised patients is rapidly growing and includes the use of more than 90 different therapeutic and preventive modalities (8) . The limited efficiency of immunotherapy observed in some patients and animal models remains to be confirmed (12, 29) . With animal models, few drugs have been reported as exhibiting an anticryptosporidial activity. It was observed that arprinocid and some sulfamides reduce the number of oocysts in feces or the number of parasites in intestinal tissue sections (19, 25) . Azithromycin and other macrolides were recently shown to reduce the severity of the ileal infection (20, 24) . We have confirmed in our model the activity of lasalocid previously reported in calves (5, 14) . Although it is difficult to extrapolate between different models, the overall activity of sinefungin appears to exceed that of other drugs tested (5) . Studies are in progress to determine optimal curative and preventive regimens of sinefungin in immunosuppressed rats.
